Atara Biotherapeutics, Inc.

AI-generated fair value estimate for this company.

Method: Net liquid assets plus risk-adjusted partnership value: $9.9M cash and short-term investments; risk-adjusted pipeline value of approximately $30M reflecting the Pierre Fabre tabelecleucel deal, including a $31M FDA-approval milestone and tiered ex-US royalties, risk-weighted at roughly 35% approval probability and discounted about 2 years at 12%; 10.04M shares outstanding.

Reasoning: Atara Biotherapeutics has minimal cash runway and near-zero recurring revenue, so value rests on net cash plus a heavily risk-adjusted view of its one concrete priced partnership asset rather than a standard DCF or unadjusted pipeline NPV.